Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant announcement, made well in advance of the payment date, underscores the company's robust financial health and unwavering commitment to
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P 500 Healthcare Sector closed the day without any explicit, significant sector-wide news driving its performance. Instead, its movements largely mirrored the
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached an unprecedented all-time high. This bullish sentiment in equities, however, unfolded against the backdrop of a
Although Amgen (currently trading at $299.86 per share) has gained 9.6% over the last six months, it has trailed the S&P 500’s 29.3% return during that period. This might have investors contemplating their next move.
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market discussions about "dividend increases," the biotechnology firm has publicly stated it does not anticipate paying dividends in the immediate future. Instead, the company has
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major indices like the Nasdaq and S&P 500 managed to eke out modest gains, the Dow's struggle underscores an underlying apprehension
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
